SCHEMBL29478348

SCHEMBL29478348

CCN(CC)C(=O)c1ccccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.62
HSP90AA1 P07900 4/20 0.56
HSP90AB1 P08238 4/20 0.56
TP53 P04637 1/20 0.55
KEAP1 Q14145 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
HMGB1 P09429 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288796 1.00 TSHR (0.62) TSHRHSP90AA1HSP90AB1TP53KEAP1
Alcohol SCHEMBL28109153 0.96 TSHR (0.59) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL266244 0.88 TSHR (0.58) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL29822323 0.87 TP53 (0.69) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL610480 0.87 TP53 (0.69) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL10146384 0.86 TSHR (0.53) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL6371982 0.82 KDM4E (0.64) TSHRTP53KEAP1MAPK1ALDH1A1
SCHEMBL30337088 0.82 TP53 (0.62) TSHRTP53TDP1ALDH1A1HPGD
SCHEMBL28972723 0.82 TP53 (0.62) TSHRTP53TDP1ALDH1A1HPGD
SCHEMBL150008 0.80 TSHR (0.75) TSHRTP53KEAP1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731209-A1 PROCESSES FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS Merck Sharp & Dohme LLC (US) 2026-04-29 EP claimed
WO-2025006295-A1 PROCESSES FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME LLC (US) 2025-01-02 WO claimed
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-07-15 US disclosed
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-05-13 US disclosed
WO-2025026436-A1 NITROGEN-CONTAINING FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 韦恩生物科技有限公司 2025-02-06 WO disclosed
CN-114539167-B Process for producing alkynyl ketone derivative 盐野义制药株式会社 2024-12-17 CN disclosed
CN-109415352-B 3-amino-1, 2, 4-triazine derivatives and their use for controlling unwanted plant growth 拜耳作物科学股份公司 2022-04-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 TSHR 3270/4885HSP90AA1 3102/4885HSP90AB1 3206/4885
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 TSHR 3270/4885HSP90AA1 3102/4885HSP90AB1 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.